These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 7403955)

  • 1. Assessment of antibody responses and protective immunity in cholera vaccinated subjects.
    Chaicumpa W; Pacharaprakiti C; Plueksawan W; Atthasishtha N
    Southeast Asian J Trop Med Public Health; 1980 Mar; 11(1):58-66. PubMed ID: 7403955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate.
    Levine MM; Black RE; Clements ML; Young CR; Lanata C; Sears S; Honda T; Finkelstein R
    Dev Biol Stand; 1983; 53():59-65. PubMed ID: 6873477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
    Svennerholm AM
    Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A one dose experimental cholera vaccine.
    Muse M; Grandjean C; Wade TK; Wade WF
    FEMS Immunol Med Microbiol; 2012 Oct; 66(1):98-115. PubMed ID: 22612159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.
    Tarique AA; Kalsy A; Arifuzzaman M; Rollins SM; Charles RC; Leung DT; Harris JB; Larocque RC; Sheikh A; Bhuiyan MS; Saksena R; Clements JD; Calderwood SB; Qadri F; Kovác P; Ryan ET
    Clin Vaccine Immunol; 2012 Apr; 19(4):594-602. PubMed ID: 22357651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pasteur oral cholera vaccine: studies of reactogenicity, clinical acceptability and immunogenicity in human volunteers.
    Pitisuttitham P; Migasena S; Prayurahong B; Supanaranond W; Suntharasamai P; Supeeranan L; Chantra A; Naksrisook S
    Southeast Asian J Trop Med Public Health; 1993 Mar; 24(1):126-9. PubMed ID: 8362286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
    Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ
    Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638.
    Talavera A; Año G; García H; Moreira T; Delgado H; Riverón L; Gil S; Miranda A; Cedré B; Valmaseda T; Pino Y; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 May; 24(18):3746-9. PubMed ID: 16085342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vibriolytic IgG immunocyte response of mice after primary and secondary immunization with cholera somatic antigens.
    Friedman H
    Immunology; 1975 Aug; 29(2):283-99. PubMed ID: 51000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier.
    Chernyak A; Kondo S; Wade TK; Meeks MD; Alzari PM; Fournier JM; Taylor RK; Kovác P; Wade WF
    J Infect Dis; 2002 Apr; 185(7):950-62. PubMed ID: 11920320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The excretion pattern and protective capacity in rabbits orally immunized with attenuated strains of Vibrio cholerae O1 biotype El Tor].
    García Sánchez HM; García Imia L; Oliva Hernández R; Pérez Quiñoy JL; Cedré Marrero B; Domínguez Iriarte R; Benítez Robles J
    Rev Cubana Med Trop; 1998; 50(2):115-9. PubMed ID: 10349429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.
    Gupta RK; Taylor DN; Bryla DA; Robbins JB; Szu SC
    Infect Immun; 1998 Jul; 66(7):3095-9. PubMed ID: 9632571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a live oral cholera vaccine in human volunteers.
    Woodward WE; Gilman RH; Hornick RB; Libonati JP; Cash RA
    Dev Biol Stand; 1976; 33():108-12. PubMed ID: 782960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.